Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted multiple share repurchases of A shares from March 8 to April 9, 2024. According to reports disclosed by the Company, the Company has repurchased millions of shares during the above periods, the number of shares repurchased and the repurchase price varies, and these repurchases are not accompanied by share write-offs. The most recent repurchase took place on April 9, 2024, on which day the company repurchased 435,400 shares of A-shares for a total payment of RMB20,046,156. This series of share repurchases is carried out in accordance with the relevant rules at the Shanghai Stock Exchange. The Company has confirmed that all relevant legal documents have been complied with and archived and that all transactions have been completed.

Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted multiple share repurchases of A shares from March 8 to April 9, 2024. According to reports disclosed by the Company, the Company has repurchased millions of shares during the above periods, the number of shares repurchased and the repurchase price varies, and these repurchases are not accompanied by share write-offs. The most recent repurchase took place on April 9, 2024, on which day the company repurchased 435,400 shares of A-shares for a total payment of RMB20,046,156. This series of share repurchases is carried out in accordance with the relevant rules at the Shanghai Stock Exchange. The Company has confirmed that all relevant legal documents have been complied with and archived and that all transactions have been completed.